Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies
Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies
10/06/20, 11:39 AM
Location
san franciscoMoney raised
$50 million
Round Type
series a
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. Federation Bio is pioneering new approaches for treating intractable diseases by combining an unprecedented number of microbial strains into highly diverse consortia, in some instances optimized with genetically engineered bacteria to enhance the immune system. The company was founded by Michael Fischbach, Ph.D., and Dylan Dodd, M.D., Ph.D., with support from Venrock.
Company Info
Location
san francisco, panamá province, panama
Additional Info
Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions, from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions. Federation Bio's lead program is in secondary hyperoxaluria, a serious renal condition that affects more than 200,000 Americans and for which there are currently no approved therapies. Additional information can be found at www.federation.bio